Drug interactions
Exenatide injectable + Insulin glargine-lixisenatide
Severity: Major
Exenatide injectable and Insulin glargine-lixisenatide: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both products are GLP-1 receptor agonists (lixisenatide in the fixed-dose combination and exenatide), so combining them duplicates therapy without a proven added benefit. Gastrointestinal adverse effects, and hypoglycemia from the insulin component, may be increased.
What this interaction means in plain words
Exenatide injectable and Insulin glargine-lixisenatide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Duplicate GLP-1 receptor agonist activity producing additive pharmacodynamic effects on insulin secretion, gastric emptying and appetite.
What to do
Avoid using two GLP-1 receptor agonists together; choose a single agent and stop the duplicate. If the combination is unavoidable, monitor blood glucose and GI tolerability closely and reduce insulin as needed.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Exenatide injectable and Insulin glargine-lixisenatide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Insulin glargine-lixisenatide
Frequently asked questions
Can I take Exenatide injectable with Insulin glargine-lixisenatide?
MediHelp rates the interaction as major. Exenatide injectable and Insulin glargine-lixisenatide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both products are GLP-1 receptor agonists (lixisenatide in the fixed-dose combination and exenatide), so combining them duplicates therapy without a proven added benefit. Gastrointestinal adverse effects, and hypoglycemia from the insulin component, may be increased.
How serious is the interaction between Exenatide injectable and Insulin glargine-lixisenatide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid using two GLP-1 receptor agonists together; choose a single agent and stop the duplicate. If the combination is unavoidable, monitor blood glucose and GI tolerability closely and reduce insulin as needed.
What other medicines interact with Insulin glargine-lixisenatide?
MediHelp also lists interactions of Insulin glargine-lixisenatide with, for example, Albiglutide, Chlorpropamide, Dulaglutide. The full list is on the Insulin glargine-lixisenatide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
